Patients | |||||||||
Number | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 |
Sex | F | F | F | F | M | F | F | F | F |
Age of onset (years) | 7 | 10 | 13 | 13 | 13 | 18 | 20 | 18 | 26 |
Follow-up (months) | 25 | 12 | 26 | 13 | 1 | 1 | 6 | 12 | 5 |
Clinical features at the disease peak | |||||||||
Psychiatric features | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
Cognitive dysfunction | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
Seizures | Yes | No | Yes | Yes | No | Yes | Yes | Yes | Yes |
Movement disorder | Yes | Yes | No | Yes | Yes | No | No | Yes | No |
Autonomic dysfunction | Yes | No | No | No | No | No | No | Yes | No |
Coma | Yes | No | No | No | No | No | No | Yes | No |
Laboratory features at the disease diagnosis | |||||||||
MRI changes | No | No | No | Yes | No | No | No | No | Yes |
EEG changes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
Disease course and therapy | |||||||||
Progression (days)a | 28 | 15 | 28 | 17 | 6 | 16 | 30 | 29 | 29 |
Time to therapy (days)b | 6 | 15 | 49 | 21 | 4 | 320 | 60 | 21 | 29 |
Recovery (days)c | 750 | 43 | 91 | 72 | 30 | 320 | 36 | 150 | 85 |
Therapyd | IVIG, CS, PE, RTX, CPA, IA, alemtuzumab, MTX, MMF | PE, CS, IVIG | PE, CS, IVIG | PE, CS, IVIG | CS, IVIG | PE, IVIG, CS | CS, IVIG | PE, IVIG, CS, RTX | PE, CS, CPA |